CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy

CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy

Introduction: Mesenchymal stromal cells (MSCs) hold the potential for application as cellular therapy products; however, there are many problems that need to be addressed before the use in clinical settings, these include the heterogeneity of MSCs, scalability in MSC production, timing and technique...

Full description

Bibliographic Details
Main Authors: Sohsuke Meshitsuka, Ryo Ninomiya, Tokiko Nagamura-Inoue, Takashi Okada, Muneyoshi Futami, Arinobu Tojo
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Regenerative Therapy
Subjects:
UC-MSCs
AAV
CRISPR/Cas9
HLA-G
Allogenic rejection
Online Access:http://www.sciencedirect.com/science/article/pii/S2352320422000955

Similar Items

Similar Items